Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion

Bristol Myers Squibb has appointed Cristian Massacesi as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will lead the company’s early- and late-stage product development across all therapeutic areas.

Dr. Massacesi began his career in the healthcare field as a medical oncologist, bringing the ethos of putting patients first into his more than 20 years of global biopharmaceutical experience.

He has a proven track record of advancing breakthrough science from early through late-stage development and global regulatory approvals, inspiring and encouraging his teams to identify novel strategies and take smart risks.

He most recently served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca.

Prior to his tenure at AstraZeneca, Dr. Massacesi held senior R&D positions at Pfizer and Novartis, where he oversaw development programs across solid tumors and hematologic malignancies.